{
  "_id": "67000255b3331c12392c30621fa197b08b255526040f90c94d4eda2a4a3cb674",
  "feed": "wall-street-journal",
  "title": "Covid-19 Treatments: What Is FDA Approved and What Is Coming Next? Monoclonal antibody drugs are authorized for emergency use, while Pfizer and Merck's pill regimens are under review",
  "text": "<p>About two-thirds of the country are fully vaccinated with the three vaccines authorized in the U.S.â€”Pfizer-BioNTech, Moderna and Johnson &amp; Johnson. Over 30 million Americans have received an additional dose.</p><p>Treatments</p><p>Treatments for Covid-19 have lagged behind the development of vaccines, but progress is picking up. Ahead of the FDA-approval announcement, Pfizer said the U.S. government had agreed to pay $5.29 billion to buy enough supplies of its promising Covid-19 pill to treat 10 million people.</p><p>Hanna Sender, Angela Calderon and Erik Brynildsen contributed to this article.</p><p>Write to Joseph Walker at joseph.walker@wsj.com</p><p>Covid-19 Treatments: What Is FDA Approved and What Is Coming Next?</p>",
  "published": "2021-11-19T15:40:00.000Z",
  "tags": [
    {
      "id": "US4781601046",
      "name": "Johnson & Johnson",
      "offsets": [
        {
          "start": 129,
          "end": 146
        }
      ],
      "nexusId": "10010560"
    }
  ]
}